Search results for "Protein"

showing 10 items of 21431 documents

Pulmonary metastasectomy in colorectal cancer: a prospective study of demography and clinical characteristics of 543 patients in the Spanish colorect…

2013

Objectives To capture an accurate contemporary description of the practice of pulmonary metastasectomy for colorectal carcinoma in one national healthcare system. Design A national registry set up in Spain by Grupo Espanol de Cirugia Metastasis Pulmonares de Carcinoma Colo-Rectal (GECMP-CCR). Setting 32 Spanish thoracic units. Participants All patients with one or more histologically proven lung metastasis removed by surgery between March 2008 and February 2010. Interventions Pulmonary metastasectomy for one or more pulmonary nodules proven to be metastatic colorectal carcinoma. Primary and secondary outcome measures The age and sex of the patients having this surgery were recorded with the…

medicine.medical_specialtyCirurgia colorectalMediastinal lymphadenopathyColorectal cancerMetastasisMetastasisCarcinoembryonic antigenMetàstasiCàncer colorectalColorectal surgerymedicineCarcinoma1506Prospective cohort studyPathological16941695biologybusiness.industryResearchGeneral surgeryGeneral Medicinemedicine.diseaseColorectal cancerSurgeryOncologybiology.protein1737Metastasectomy1717business
researchProduct

Complement activation by oxidatively modified low-density lipoproteins

1999

Background Oxidatively modified low-density lipoproteins (LDLs) have been implicated in the pathogenesis of atherosclerosis and are found in human vascular lesions. There is increasing evidence that complement activation may also play a role in atherogenesis. Activated complement proteins have been demonstrated to be present in early atherosclerotic lesions, and lipids isolated from lesions have been shown to activate complement, hence their designation as lesion complement activator (LCA). The question now arose whether oxidized LDLs would also activate complement. Material and methods The complement-activating capacity of a lesion complement activator preparation and of minimally as well …

medicine.medical_specialtyClinical BiochemistryInflammationImmunoelectrophoresis030204 cardiovascular system & hematologyBiochemistryLipid peroxidationPathogenesisLesion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryVascular diseaseGeneral Medicinemedicine.diseaseComplement systemComplement (complexity)EndocrinologyBiochemistrylipids (amino acids peptides and proteins)medicine.symptomEuropean Journal of Clinical Investigation
researchProduct

Recent advances on stearoyl-Coa desaturase regulation in fatty liver diseases.

2012

Stearoyl-CoA desaturase 1 (SCD-1) is a delta-9 fatty acid desaturase that catalyzes the synthesis of monounsaturated fatty acids. Indeed, SCD-1 is the critical control point regulating hepatic lipogenesis and lipid oxidation. Due to its central role in lipid metabolism in the liver, recent studies have focused on the involvement of SCD-1 in the development of fatty liver during obesity, diabetes mellitus, hypertension, excessive alcohol consumption, and in subjects with high triglyceride blood concentrations. The accumulation of fat in liver cells can be a sign that harmful conditions are developing, possibly associated with or leading to inflammation of the liver. This review evaluates the…

medicine.medical_specialtyClinical Biochemistrychemistry.chemical_compoundLipid oxidationInternal medicineDiabetes mellitusmedicineAnimalsHumansPharmacologyTriglyceridebiologyFatty liverLipid metabolismmedicine.diseaseFatty LiverStearoyl-CoA DesaturaseEndocrinologyFatty acid desaturasechemistrybiology.proteinFatty Acids UnsaturatedSteatosisStearoyl-CoA DesaturaseFatty Liver AlcoholicTranscription FactorsCurrent drug metabolism
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct

Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon

2015

Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. It is estimated that each year TBIs are associated with 1.1 million emergency department visits, 235,000 hospitalizations, and 50,000 deaths (1). Despite improvements in medical interventions, there are still no neuroprotective agents available to counteract secondary or delayed damage to the traumatically injured human brain or to promote its repair. TBI encompasses heterogeneous etiologic, anatomical, and molecular patterns of injury that exhibit different propensities to cause cerebral damage. Without careful consideration of individual injuries, the results of therapeutic trials remain difficu…

medicine.medical_specialtyClinical Trials as Topicbusiness.industryTraumatic brain injurySettore MED/27 - NeurochirurgiaMedicine (all)Neuroprotective AgentRecombinant Proteinmedicine.diseaseRecombinant ProteinsEpoetin AlfaNeuroprotective AgentsErythropoietinBrain InjuriesBrain InjurieReceptors ErythropoietinMedicineHumansSurgeryNeurology (clinical)businessIntensive care medicineErythropoietinmedicine.drugHuman
researchProduct

Classification, diagnosis, and approach to treatment for angioedema:consensus report from the Hereditary Angioedema International Working Group

2014

Angioedema is defined as localized and self-limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoactive mediator(s). When angioedema recurs without significant wheals, the patient should be diagnosed to have angioedema as a distinct disease. In the absence of accepted classification, different types of angioedema are not uniquely identified. For this reason, the European Academy of Allergy and Clinical Immunology gave its patronage to a consensus conference aimed at classifying angioedema. Four types of acquired and three types of hereditary angioedema were identified as separate forms from the analysis o…

medicine.medical_specialtyClinical immunologyImmunologyDiseaseC1-inhibitorurticariaimmune system diseasesVasoactivemedicineHumansImmunology and Allergycardiovascular diseasesAngioedemaskin and connective tissue diseaseseducationAngioedemabiologybusiness.industryangioedemaConsensus conferencefood and beveragesInternational working groupmedicine.diseaseDermatologySurgerydermatologyHereditary angioedemabiology.proteinmedicine.symptombusinessclinical immunology
researchProduct

Platelet-rich fibrin for wound healing of palatal donor sites of free gingival grafts: Systematic review and meta-analysis.

2020

Made available in DSpace on 2021-06-25T10:22:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-01-01 Background: Platelet-rich fibrin (PRF) has been referred to as a second-generation platelet concentrate, associated with improvements on the healing of palatal wounds followed by FGG harvesting. The aim of this systematic review and meta-analysis was to assess the complete wound epithelialization and postoperative pain when PRF was used in palatal wounds following free gingival graft (FGG) harvesting. Material and Methods: PubMed (Medline), EMBASE and Scopus were searched by two independent individuals up to and including March 2020 in order to identify controlled and randomized cont…

medicine.medical_specialtyCochrane collaborationbiologybusiness.industryOral surgeryWound healingReviewFibrinPlatelet-rich fibrinSurgeryClinical trialoral surgery proceduresMeta-analysisbiology.proteinpostoperativeMedicinepainPeriodontologyPlatelet concentratebusinessWound healingGeneral DentistryUNESCO:CIENCIAS MÉDICASJournal of clinical and experimental dentistry
researchProduct

Effect of the stable prostacyclin analogue iloprost on water and electrolyte transfer of the rat ileum and colon in vivo.

1988

The effect of iloprost on water and ion transfer was measured simultaneously in tied-off loops of the rat ileum and colon in vivo. (1) In the ileal loops iloprost had no effect on water and ion transfer neither by intraluminal, nor intraaortal or intravenous application. (2) In the colonic loops only intraaortal bolus application of the high dose of 500 micrograms iloprost significantly decreased net water, sodium and chloride absorption, but did not induce net secretion. (3) Inhibition of endogenous prostaglandin synthesis by indomethacin did not change net water and electrolyte transfer in the ileum and colon. (4) Under this pretreatment i.v.-application of 100 micrograms iloprost, ineffe…

medicine.medical_specialtyColonSodiumClinical BiochemistryIndomethacinchemistry.chemical_elementProstaglandinEndogenyIleumProstacyclinBiochemistrychemistry.chemical_compoundChloridesIn vivoIleumInternal medicinemedicineAnimalsIloprostReceptorSodiumRats Inbred StrainsGeneral MedicineWater-Electrolyte BalanceEpoprostenolRatsmedicine.anatomical_structureEndocrinologychemistrycardiovascular systemPotassiumlipids (amino acids peptides and proteins)Iloprostmedicine.drugEuropean journal of clinical investigation
researchProduct

Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension.

2012

There are few clinical trials that provide evidence to support the hypothesis that combined therapies offer a favorable risk-benefit ratio in the reduction of cardiovascular mortality and morbidity. Combined therapies containing an angiotensin-converting enzyme inhibitor (ACEI) with a calcium channel blocker (CCB) is one of the recommended combinations in the reappraisal of the European Society of Hypertension.The authors have performed a systematic review of the available clinical evidence on the use of combined therapies containing an ACEI with a CCB versus other combinations in the management of arterial hypertension (HT) and in the reduction of cardiovascular morbidity/mortality, accord…

medicine.medical_specialtyCombination therapymedicine.drug_classMEDLINEAngiotensin-Converting Enzyme InhibitorsCalcium channel blockerPharmacologyPharmacotherapyRisk FactorsInternal medicinemedicineHumansPharmacology (medical)Antihypertensive AgentsPharmacologyClinical Trials as Topicbiologybusiness.industryAngiotensin-converting enzymeGeneral MedicineCalcium Channel BlockersClinical trialSystematic reviewTreatment OutcomeEnzyme inhibitorCardiovascular DiseasesHypertensionbiology.proteinDrug Therapy CombinationbusinessExpert opinion on pharmacotherapy
researchProduct

Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management

2013

Abstract Introduction and objectives Although atherogenic dyslipidemia is a recognized cardiovascular risk factor, it is often underassessed and thus undertreated and poorly controlled in clinical practice. The objective of this study was to reach a multidisciplinary consensus for the establishment of a set of clinical recommendations on atherogenic dyslipidemia to optimize its prevention, early detection, diagnostic evaluation, therapeutic approach, and follow-up. Methods After a review of the scientific evidence, a scientific committee formulated 87 recommendations related to atherogenic dyslipidemia, which were grouped into 5 subject areas: general concepts (10 items), impact and epidemi…

medicine.medical_specialtyConsensusDelphi TechniqueGuidelines as TopicScientific evidenceTherapeutic approachRisk FactorsMultidisciplinary approachEpidemiologymedicineHumansRisk factorDyslipidemiascomputer.programming_languageAtherogenic dyslipidemiaEvidence-Based Medicinebusiness.industryExpert consensusGeneral MedicineAtherosclerosisAtherogenic dyslipidemia Cardiovascular risk Consenso Consensus Delphi Dislipemia aterogénica HDL-C LDL-C Riesgo cardiovascular high-density lipoprotein cholesterol low-density lipoprotein cholesterolCardiovascular DiseasesFamily medicinePhysical therapybusinesscomputerDelphiRevista Española de Cardiología (English Edition)
researchProduct